Risankizumab in CD: Outcomes Remain Stable up to 3 Years
STOCKHOLM, Sweden — Long-term data on risankizumab (Skyrizi) in moderate to severe Crohn's disease (CD) show that clinical remission and ...
Read moreDetailsSTOCKHOLM, Sweden — Long-term data on risankizumab (Skyrizi) in moderate to severe Crohn's disease (CD) show that clinical remission and ...
Read moreDetails© 2023 earth-news.info
© 2023 earth-news.info